Abstract
Neuromyelitis optica (NMO) is a relapsing autoimmune disease targeting the spinal cord and optic nerve leading to paralysis and blindness. Current treatment for acute NMO attacks is immunosuppression with high-dose corticosteroids and/or plasmapheresis. Preclinical animal studies suggest that bevacizumab might be beneficial in limiting the extent of inflammation during a NMO relapse by reducing the disruption of the blood-brain barrier. We carried out an open-label phase 1b safety and proof-of-concept trial in 10 participants with NMO immunoglobulin G seropositive NMO, NMO spectrum disease and those at high risk for developing NMO/NMO spectrum disease who presented with an acute attack of transverse myelitis, optic neuritis or brainstem inflammation. In addition to treating with 1 g of daily intravenous methylprednisolone, we infused 10 mg/kg of bevacizumab intravenously on day 1 of treatment. The primary outcome measure was safety and the secondary outcome measure was efficacy. Of the 10 participants enrolled, five presented with acute transverse myelitis, four with acute optic neuritis and one with a brainstem lesion. Bevacizumab was safe in all 10 participants, with only one serious adverse event within the 90-day follow up ...Continue Reading
References
Sep 25, 1999·Neurology·D M WingerchukB G Weinshenker
May 24, 2006·Neurology·D M WingerchukB G Weinshenker
Jun 15, 2007·Archives of Neurology·Brian G Weinshenker
Aug 21, 2007·Lancet Neurology·Dean M WingerchukBrian G Weinshenker
Dec 25, 2009·Rinshō shinkeigaku = Clinical neurology·Brian G Weinshenker
Jan 6, 2011·Neurology·Eric M ThompsonEdward A Neuwelt
Aug 24, 2011·Neurology·Marc C Chamberlain
Nov 22, 2011·Journal of Neurology, Neurosurgery, and Psychiatry·Fumitaka ShimizuTakashi Kanda
Jun 2, 2012·The Journal of Clinical Investigation·Azeb Tadesse ArgawGareth R John
Sep 14, 2013·Disability and Rehabilitation·Kerry MutchAnu Jacob
Oct 1, 2012·Multiple Sclerosis and Related Disorders·Dorlan J KimbroughUNKNOWN GJCF-CC&BR
Oct 16, 2014·Drugs·Gillian M Keating
Citations
Dec 27, 2015·Current Treatment Options in Neurology·Remi A KesslerMichael Levy
Mar 18, 2017·Current Opinion in Neurology·Romain MarignierSandra Vukusic
Apr 18, 2018·Journal of Clinical Pharmacology·Daohong Chen
Jul 25, 2019·Expert Review of Neurotherapeutics·Alice BruscoliniAlessandro Lambiase
Feb 20, 2020·Expert Opinion on Therapeutic Targets·Lukmanee TradtrantipAlan S Verkman
Apr 2, 2020·Expert Opinion on Biological Therapy·Ankelien DuchowJudith Bellmann-Strobl
Mar 29, 2019·Current Opinion in Rheumatology·Andrew R Romeo, Benjamin M Segal
Jun 14, 2020·Neuroscience Bulletin·Wenli ZhuYaping Yan
May 4, 2018·Current Treatment Options in Neurology·Grace Y Gombolay, Tanuja Chitnis
Jan 10, 2019·Drugs·Nicolas CollonguesJérôme de Seze
Jan 5, 2021·Frontiers in Neurology·Tao XueZhong Wang
Jan 10, 2021·Pharmaceuticals·Jan TraubMartin S Weber
Sep 29, 2020·Journal of Neuroimmunology·Xiaoyu MaWei Qiu
Apr 29, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Laura CacciaguerraMassimo Filippi
Jul 25, 2021·Cancers·Lynn BitarMirko H H Schmidt
Aug 1, 2021·Multiple Sclerosis and Related Disorders·Carolina M RimkusClaudia da Costa Leite
Sep 18, 2021·Journal of Neuroinflammation·Edgar Carnero Contentti, Jorge Correale